Janssen-Cilag Submits for IMBRUVICA Indication Extension in Untreated Mantle Cell Lymphoma
Janssen-Cilag International NV has announced the submission seeking approval for an indication extension of IMBRUVICA...
Janssen
XtalPi’s AI Platform XtalFold Secures Licensing Deal with Janssen Biotech, Enhancing Biologics Discovery
XtalPi (QuantumPharm, HKG: 2228) a leading AI-driven drug discovery firm based in Shenzhen and known...
Xtalpi Inc. Makes a Splash with HKD 1.13 Billion IPO on Hong Kong Stock Exchange
XtalPi (QuantumPharm, HKG: 2228) has successfully conducted an initial public offering (IPO) on the Hong...
GSK Acquires Global Rights to Janssen’s Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal
GlaxoSmithKline (GSK; NYSE: GSK) has announced the acquisition of global rights to the hepatitis B...
Janssen’s Rybrevant Combo Meets Primary Endpoint in Advanced NSCLC Study
Janssen, a subsidiary of Johnson & Johnson (J&J; NYSE: JNJ), has released an update on...
HHS Releases List of 10 Drugs for Medicare Price Negotiations Starting 2026
The Department of Health and Human Services (HHS) in the US has released a list...
Janssen Submits Indication Extension Application for Balversa in Urothelial Carcinoma Treatment
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has submitted an indication extension...
Janssen Submits Rybrevant for FDA Review as First-Line NSCLC Treatment
Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has submitted an additional indication for review...
European Commission Grants Conditional Approval for Janssen’s Talvey in Multiple Myeloma
The European Commission (EC) has granted conditional approval to Johnson & Johnson’s (J&J; NYSE: JNJ)...
J&J Subsidiary Janssen Wins FDA Approval for Akeega in BRCA-Positive mCRPC Treatment
The US Food & Drug Administration (FDA) has granted marketing approval to Johnson & Johnson...
Janssen’s Talvey Receives FDA Accelerated Approval for Relapsed/Refractory Multiple Myeloma
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) announced last week that it...
Janssen’s Sirturo (Bedaquiline) Expands Indication to Include Adolescents with MDR-TB
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced that the National...
Biomm Secures Late-Stage Biosimilar Candidate BAT2206 from Bio-Thera Solutions
Brazil-based biotechnology company Biomm (BVMF: BIOM3) has announced that it has in-licensed the late-stage biosimilar...
Jiangsu Kanion Pharmaceutical Gets FDA Approval for KYS202002A Clinical Study in Multiple Myeloma
China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving the green light from...
Cellular Biomedicine Group Inc. and Janssen Biotech, Inc. Announce Global Collaboration for CAR-T Therapies
China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG), emerging from a merger deal in...
Janssen’s Spravato Approved by NMPA for Adult Depression and Suicidal Ideation Treatment
Janssen’s Spravato (esketamine) has been granted approval by the National Medical Products Administration (NMPA) in...
Legend Biotech and Janssen Partner with Novartis on Carvykti Manufacturing and Clinical Supply
Legend Biotech Corporation (NASDAQ: LEGN), a China-based biotech firm, and its US partner Janssen Pharmaceutical...
Janssen Withdraws Carvykti from UK Market Amid Manufacturing Concerns
US-based Janssen Pharmaceutical reportedly decided to withdraw Carvykti (ciltacabtagene autoleucel; cilta-cel) from the UK market...
Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing...
Novartis’ LNP023 and Janssen’s Tremfya on Track for Breakthrough Designations
The Center for Drug Evaluation (CDE) website indicates that Swiss major Novartis’ (NYSE: NVS) LNP023...